Current Report Filing (8-k)
January 29 2020 - 3:04PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): January 29, 2020
Bio-Matrix
Scientific Group, Inc.
(Exact
Name of Company as Specified in Charter)
Commission
File Number: 0-32201
|
|
Delaware
|
33-0824714
|
(State
or Other Jurisdiction of
Incorporation)
|
(IRS
Employer Identification
Number)
|
1204
Tangerine Street, El Cajon, CA 92021
(Address
of Principal Executive Offices, Zip Code)
Company’s
telephone number, including area code: (619)
822-2602
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
5.03 Amendments to Articles of Incorporation
On
January 29, 2020 Bio-Matrix Scientific Group, Inc. (the “Company”) submitted a Certificate of Amendment (“Amendment”)
to its Certificate of Incorporation with the State of Delaware
The
Amendment reduces the number of shares of common stock the Company is authorized to issue from 16,000,000,000 shares of common
stock to 100,000,000 shares of common stock.
The
Amendment authorizes a reverse stock split of its issued and outstanding common stock and all classes of issued and outstanding
preferred stock at an exchange ratio of one new share for every 2,000 old shares. Fractional shares of stock shall be rounded
up to the nearest whole share. Par Value shall remain $0.0001.
Both
of the abovementioned changes shall be effective February 18, 2020.
Item
9.01 Exhibits.
Exhibit
No.
|
|
Description
of Exhibit
|
3(i)
|
|
AMENDMENT
TO CERTIFICATE OF INCORPORATION
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
BIO-MATRIX
SCIENTIFIC GROUP, INC.
|
|
|
Dated:
January 29, 2020
|
By: /s/
Timothy Foat
|
|
Timothy
Foat
|
|
Chief
Executive Officer
|